A Secret Weapon For Oteseconazole
Kantarjian et al53 assessed the efficacy and safety of dasatinib, as when compared with imatinib, for the initial-line treatment of CML-CP. Five hundred and nineteen people with newly diagnosed CML-CP ended up randomly assigned to obtain dasatinib in a dose of 100 mg when every day (259 people) or imatinib at a dose of 400 mg at the time every day